Carisma Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	52.63	19.63	14.92	9.83	-	-
Revenue Growth (YoY)	159.68%	31.59%	51.71%	-	-	-
Cost of Revenue	27.36	59.67	74.13	56.62	34.39	-
Gross Profit	25.28	-40.04	-59.21	-46.78	-34.39	-
Selling, General & Admin	12.43	20.14	29.53	9.38	6.41	5.09
Research & Development	-	-	-	-	-	23.29
Operating Expenses	12.43	20.14	29.53	9.38	6.41	28.38
Operating Income	12.85	-60.18	-88.73	-56.16	-40.79	-28.38
Interest Expense	-	-	-	-3.15	-	-
Interest & Investment Income	1.3	1.7	1.94	-	0.01	0.03
Other Non Operating Income (Expenses)	0.04	-	-0.08	-1.92	-	-
EBT Excluding Unusual Items	14.19	-58.48	-86.88	-61.23	-40.78	-28.35
Merger & Restructuring Charges	-2	-2	-	-	-	-
Pretax Income	8.04	-60.48	-86.88	-61.23	-40.78	-28.35
Net Income	8.04	-60.48	-86.88	-61.23	-40.78	-28.35
Net Income to Common	8.04	-60.48	-86.88	-61.23	-40.78	-28.35
Shares Outstanding (Basic)	42	41	34	2	1	1
Shares Outstanding (Diluted)	42	41	34	2	1	1
Shares Change (YoY)	1.84%	23.66%	1475.33%	96.30%	1.95%	-
EPS (Basic)	0.19	-1.46	-2.59	-28.77	-37.62	-26.66
EPS (Diluted)	0.19	-1.46	-2.59	-28.77	-37.62	-26.66
Free Cash Flow	-22.42	-60.04	-82.31	-9.78	-39.2	-27.45
Free Cash Flow Per Share	-0.54	-1.45	-2.46	-4.59	-36.16	-25.82
Gross Margin	48.03%	-203.96%	-	-	-	-
Operating Margin	24.41%	-306.54%	-594.75%	-571.10%	-	-
Profit Margin	15.28%	-308.05%	-582.34%	-622.60%	-	-
Free Cash Flow Margin	-42.59%	-305.83%	-551.71%	-99.41%	-	-
EBITDA	14.18	-56.83	-85.89	-54.27	-40.11	-27.93
EBITDA Margin	26.94%	-289.45%	-	-	-	-
D&A For EBITDA	1.33	3.35	2.84	1.89	0.68	0.45
EBIT	12.85	-60.18	-88.73	-56.16	-40.79	-28.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.